BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy

Diana Meckbach, Ulrike Keim, Sabina Richter, Ulrike Leiter, Thomas K Eigentler, Jürgen Bauer, Annette Pflugfelder, Petra Büttner, Claus Garbe and Benjamin Weide

PLOS ONE, 2014, vol. 9, issue 2, 1-7

Abstract: Background: The impact of BRAF tumor mutations on the natural course of disease of melanoma patients is controversial. Patients and Methods: We analyzed the mutational status and overall survival of 215 patients receiving treatment with dacarbazine or temozolomide. All patients who started first-line treatment at our institution between 2000 and 2010 were included to prevent selection and bias due to thereafter arising therapeutic options. Results: No patient received BRAF- or MEK-inhibitors during follow-up. Survival was associated with the pattern of visceral involvement, the presence of brain metastases and the serum lactate dehydrogenase level (all p

Date: 2014
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0089218 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 89218&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0089218

DOI: 10.1371/journal.pone.0089218

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().